Antibodies | Selected Papers on Monoclonal Antibodies
We are pleased to highlight 15 notable papers on monoclonal antibodies published in Antibodies (ISSN: 2073-4468) in 2024 and 2025. We invite you to explore these contributions, which reflect recent advances and emerging directions in monoclonal antibodies.
1. “A Narrative Review of the State of the Art of CCR4-Based Therapies in Cutaneous T-Cell Lymphomas: Focus on Mogamulizumab and Future Treatments”
by Corrado Zengarini, Alba Guglielmo, Martina Mussi, Giovanna Motta, Claudio Agostinelli, Elena Sabattini, Bianca Maria Piraccini and Alessandro Pileri
Antibodies 2024, 13(2), 32; https://doi.org/10.3390/antib13020032
Available online: https://www.mdpi.com/2073-4468/13/2/32
2. “Immune-Related Adverse Events Associated with Atezolizumab: Insights from Real-World Pharmacovigilance Data”
by Connor Frey and Mahyar Etminan
Antibodies 2024, 13(3), 56; https://doi.org/10.3390/antib13030056
Available online: https://www.mdpi.com/2073-4468/13/3/56
3. “Functional Activity of Cytokine-Induced Killer Cells Enhanced by CAR-CD19 Modification or by Soluble Bispecific Antibody Blinatumomab”
by Silvia Zaninelli, Silvia Panna, Sarah Tettamanti, Giusi Melita, Andrea Doni, Francesca D’Autilia, Rut Valgardsdottir, Elisa Gotti, Alessandro Rambaldi, Josée Golay et al.
Antibodies 2024, 13(3), 71; https://doi.org/10.3390/antib13030071
Available online: https://www.mdpi.com/2073-4468/13/3/71
4. “Inter-Antibody Variability in the Clinical Pharmacokinetics of Monoclonal Antibodies Characterized Using Population Physiologically Based Pharmacokinetic Modeling”
by Mokshada Kumar, Sravani Lanke, Alka Yadav, Mfonabasi Ette, Donald E. Mager and Dhaval K. Shah
Antibodies 2024, 13(3), 54; https://doi.org/10.3390/antib13030054
Available online: https://www.mdpi.com/2073-4468/13/3/54
5. “Therapeutic Drug Monitoring of Infliximab and Adalimumab through Concentration and Anti-Drug Antibodies Assessment; Comparison of Sanquin Diagnostics and Theradiag Assays”
by Wim H. M. Vroemen, Shakira S. Agata, Joyce J. B. C. van Beers and Jan G. M. C. Damoiseaux
Antibodies 2024, 13(3), 73; https://doi.org/10.3390/antib13030073
Available online: https://www.mdpi.com/2073-4468/13/3/73
6. “Cost-Effective Method for Full-Length Sequencing of Monoclonal Antibodies from Hybridoma Cells”
by Sarah Döring, Georg Tscheuschner, Sabine Flemig, Michael G. Weller and Zoltán Konthur
Antibodies 2025, 14(3), 72; https://doi.org/10.3390/antib14030072
Available online: https://www.mdpi.com/2073-4468/14/3/72
7. “Monoclonal Antibodies and Small-Molecule Therapies for Lichen Planus: Targeted Immunomodulation and Emerging Evidence”
by Francois Rosset, Nadia Sciamarrelli, Luca Mastorino, Valentina Pala, Sara Boskovic, Eleonora Bongiovanni, Orsola Crespi, Yingying Liao, Simone Ribero and Pietro Quaglino
Antibodies 2025, 14(3), 79; https://doi.org/10.3390/antib14030079
Available online: https://www.mdpi.com/2073-4468/14/3/79
8. “Impact of Light-Chain Variants on the Expression of Therapeutic Monoclonal Antibodies in HEK293 and CHO Cells”
by Alexander Veber, Dennis Lenau, Polyniki Gkragkopoulou, David Kornblüh Bauer, Ingo Focken, Wulf Dirk Leuschner, Christian Beil, Sandra Weil, Ercole Rao and Thomas Langer
Antibodies 2025, 14(3), 53; https://doi.org/10.3390/antib14030053
Available online: https://www.mdpi.com/2073-4468/14/3/53
9. “Diversity in the HLA-I Recognition of HLA-F Monoclonal Antibodies: HLA-F or HLA-Ib Monospecific, HLA-E or HLA-G Bispecific Antibodies with or without HLA-Ia Reactivity”
by Mepur H. Ravindranath, Narendranath M. Ravindranath, Carly J. Amato-Menker, Fatiha El Hilali and Edward J. Filippone
Antibodies 2024, 13(1), 8; https://doi.org/10.3390/antib13010008
Available online: https://www.mdpi.com/2073-4468/13/1/8
10. “The Role of Monoclonal Antibodies as Therapeutics in HPV-Related Head and Neck Cancers: An Updated Review”
by Michael Zalin, Shaan Patel, Carter Coggins and Vikrant Rai
Antibodies 2025, 14(2), 37; https://doi.org/10.3390/antib14020037
Available online: https://www.mdpi.com/2073-4468/14/2/37